SG148202A1 - Quinazolinone compounds as anticancer agents - Google Patents

Quinazolinone compounds as anticancer agents

Info

Publication number
SG148202A1
SG148202A1 SG200808730-6A SG2008087306A SG148202A1 SG 148202 A1 SG148202 A1 SG 148202A1 SG 2008087306 A SG2008087306 A SG 2008087306A SG 148202 A1 SG148202 A1 SG 148202A1
Authority
SG
Singapore
Prior art keywords
quinazolinone compounds
anticancer agents
quinazolinone
compounds
alone
Prior art date
Application number
SG200808730-6A
Other languages
English (en)
Inventor
Weibo Wang
Liana M Lagniton
Ryan N Constantine
Manoj C Desai
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of SG148202A1 publication Critical patent/SG148202A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200808730-6A 2003-11-25 2004-11-24 Quinazolinone compounds as anticancer agents SG148202A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52505903P 2003-11-25 2003-11-25

Publications (1)

Publication Number Publication Date
SG148202A1 true SG148202A1 (en) 2008-12-31

Family

ID=34632957

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200808730-6A SG148202A1 (en) 2003-11-25 2004-11-24 Quinazolinone compounds as anticancer agents

Country Status (17)

Country Link
US (2) US7939539B2 (cg-RX-API-DMAC7.html)
EP (1) EP1689724B1 (cg-RX-API-DMAC7.html)
JP (2) JP4778439B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060127413A (cg-RX-API-DMAC7.html)
CN (1) CN1886384A (cg-RX-API-DMAC7.html)
AT (1) ATE538103T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004293464A1 (cg-RX-API-DMAC7.html)
CA (1) CA2546932A1 (cg-RX-API-DMAC7.html)
CY (1) CY1112478T1 (cg-RX-API-DMAC7.html)
DK (1) DK1689724T3 (cg-RX-API-DMAC7.html)
ES (1) ES2376552T3 (cg-RX-API-DMAC7.html)
IL (1) IL175714A0 (cg-RX-API-DMAC7.html)
PL (1) PL1689724T3 (cg-RX-API-DMAC7.html)
PT (1) PT1689724E (cg-RX-API-DMAC7.html)
SG (1) SG148202A1 (cg-RX-API-DMAC7.html)
SI (1) SI1689724T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005051922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
AU2003270015A1 (en) * 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
DK1737831T3 (da) 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
EP1786265A4 (en) * 2004-08-30 2009-08-19 Smithkline Beecham Corp NEW COMPOSITIONS AND PROCESSING METHODS
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
AU2009215073A1 (en) * 2008-02-14 2009-08-20 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
CN101250189B (zh) * 2008-03-25 2010-06-16 中山大学 双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN101857595B (zh) * 2010-05-21 2012-11-21 中山大学 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009B (zh) * 2010-07-30 2012-04-04 江苏昊华精细化工有限公司 医药中间体4(h)喹唑酮的制造方法
CN101967127B (zh) * 2010-09-28 2013-05-29 中山大学 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
CN103012291B (zh) * 2012-12-17 2014-09-03 中山大学 一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯3-激酶的抑制劑
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6743015B2 (ja) 2014-12-15 2020-08-19 バイエル ファーマ アクチエンゲゼルシャフト Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
WO2016207104A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
IL292631A (en) 2019-10-31 2022-07-01 Holosmedic Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same
KR102682775B1 (ko) 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
KR20220148758A (ko) 2021-04-29 2022-11-07 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102862736B1 (ko) * 2022-12-07 2025-09-22 부산대학교 산학협력단 신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329418A1 (de) * 1993-09-01 1995-03-02 Agfa Gevaert Ag Gelbkuppler
EP1226129B1 (en) * 1999-10-27 2006-05-24 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP4267838B2 (ja) * 2001-03-30 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
US6677110B2 (en) * 2001-03-30 2004-01-13 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
JP2002296741A (ja) * 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP4267840B2 (ja) * 2001-04-20 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002318442A (ja) * 2001-04-20 2002-10-31 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
CA2465491A1 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE372341T1 (de) * 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
PL1689724T3 (pl) 2012-05-31
JP4778439B2 (ja) 2011-09-21
PT1689724E (pt) 2012-02-06
US7939539B2 (en) 2011-05-10
EP1689724B1 (en) 2011-12-21
CY1112478T1 (el) 2015-12-09
CN1886384A (zh) 2006-12-27
JP2011084570A (ja) 2011-04-28
ATE538103T1 (de) 2012-01-15
ES2376552T3 (es) 2012-03-14
WO2005051922A1 (en) 2005-06-09
IL175714A0 (en) 2006-09-05
SI1689724T1 (sl) 2012-04-30
KR20060127413A (ko) 2006-12-12
US20110190293A1 (en) 2011-08-04
US20050209254A1 (en) 2005-09-22
DK1689724T3 (da) 2012-02-27
EP1689724A1 (en) 2006-08-16
JP2007512368A (ja) 2007-05-17
AU2004293464A1 (en) 2005-06-09
CA2546932A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
IL175714A0 (en) Quinazolinone compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200503719A (en) Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents
WO2004006859A3 (en) Platinum compound
TW200718689A (en) 2-Amino-quinazolin-5-ones
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
PH12019501328A1 (en) 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
PH12022552487A1 (en) Deuterated oxophenylarsine compound and use thereof
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY